Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumour size by up to 70 per cent and decrease in tumour metastasis by up to 50 per cent
A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant, could reduce the size of prostate tumour by up to 70 per cent and suppress its spread or metastasis by half.
Prostate cancer is one of the most commonly diagnosed cancers worldwide. However, currently available therapies for metastatic prostate cancer are only marginally effective. Hence, there is a need for more novel treatment alternatives and options.
“Although the diverse anti-cancer effects of nimbolide have been reported in different cancer types, its potential effects on prostate cancer initiation and progression have not been demonstrated in scientific studies. In this research, we have demonstrated that nimbolide can inhibit tumour cell viability – a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components – and induce programmed cell death in prostate cancer cells,” said Assoc Prof Sethi.
Nimbolide: promising effects on prostate cancer
Cell invasion and migration are key steps during tumour metastasis. The NUS-led study revealed that nimbolide can significantly suppress cell invasion and migration of prostate cancer cells, suggesting its ability to reduce tumour metastasis.
The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumour was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects.
“This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumour growth and metastasis,” explained Assoc Prof Sethi. “We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumour,” he added.
The findings of the study were published in the April 2016 issue of the scientific journal Antioxidants & Redox Signaling. This work was carried out in collaboration with Professor Goh Boon Cher of Cancer Science Institute of Singapore at NUS, Professor Hui Kam Man of National Cancer Centre Singapore and Professor Ahn Kwang Seok of Kyung Hee University.
Neem – The medicinal plant
The neem plant belongs to the mahogany tree family that is originally native to India and the Indian sub-continent, but is now also commonly found in Singapore. It has been part of traditional Asian medicine for centuries and is typically used in Indian Ayurvedic medicine. Today, neem leaves and bark have been incorporated into many personal care products such as soaps, toothpaste, skincare and even dietary supplements. Neem seedlings can also be obtained from the Indian flower shops at Campbell Lane and Buffalo Road areas within Serangoon Road in Singapore.
The team is looking to embark on a genome-wide screening or to perform a large-scale study of proteins to analyse the side-effects and determine other potential molecular targets of nimbolide. They are also keen to investigate the efficacy of combinatory regimen of nimbolide and approved drugs such as docetaxel and enzalutamide for future prostate cancer therapy.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26on November 20, 2019 at 4:20 am
Prostate cancer is a highly heterogeneous, multifactorial disease with a complex underlying biology that evolves from initial tumorigenesis to metastatic spread and castration-resistance. During ...
- Anixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek™ Prostate Cancer Studyon November 20, 2019 at 4:18 am
IUI will provide patient samples for Anixa's ongoing prostate cancer study, including support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test. IUI is one of several sites ...
- An exome-wide rare variant analysis of Korean men identifies three novel genes predisposing to prostate canceron November 20, 2019 at 3:12 am
Since prostate cancer is highly heritable, common variants associated with prostate cancer have been studied in various populations, including those in Korea. However, rare and low-frequency variants ...
- Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Canceron November 19, 2019 at 7:59 pm
What Myovant Said About Relugolix Myovant said the Phase 3 study dubbed HERO that evaluated once-daily oral relugolix 120mg in men with advanced prostate cancer met the primary efficacy endpoint, as ...
- Hormone Refractory Prostate Cancer (HRPCA) Market To Reach USD 15.64 Billion By 2026| Reports And Dataon November 19, 2019 at 5:50 pm
New york, Nov. 19, 2019 (GLOBE NEWSWIRE) -- The global hormone refractory prostate cancer (HRPCA) market is forecast to reach USD 15.64 Billion by 2026, according to a new report by Reports and Data.
- With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next yearon November 19, 2019 at 12:33 pm
A Peninsula company that didn’t exist four years ago is on the cusp of asking regulators early next year to approve versions of its marquee drug against a debilitating condition in women as well as a ...
- Prostate cancer patients receiving care at MultiD clinic more likely to be advised about treatment choiceson November 19, 2019 at 9:46 am
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of ...
- A computer model has learned to detect prostate canceron November 19, 2019 at 4:19 am
According to Yuri Kistenev, in the analysis, artificial intelligence not only detects the presence of cancer cells, but also evaluates the tumor according to the Gleason score, which is traditionally ...
- Sleeping Habits May Increase Your Risk Of Developing The Deadly Prostate Canceron November 19, 2019 at 3:40 am
The most common form of cancer that afflicts men in the UK is prostate cancer. Since no cure has been found yet, it is vital you know the risks associated with the development of the disease. Several ...
via Bing News